Close Menu

NEW YORK (GenomeWeb) – Great Basin Scientific announced today that it has priced a public stock offering of 39.2 million units at $.16 per unit.

The company expects gross proceed of about $6.3 million and net proceeds of about $5.6 million, which it plans to use to fund R&D, support and expand its manufacturing capabilities, and for general corporate purposes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.